- active not recruitingPHASE3
Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients
This study looks at a new drug (BMS-663068) for people with HIV-1 who have tried many treatments and whose current medication isn’t working well. It wants to see if this new drug can help them, especially if their HIV has become resistant to other medicines.
United States · Argentina · Australia - recruitingTherapeutic exploratory (Phase II)
A Randomized, Double-Blind (Sponsor-Unblinded), Placebo-Controlled, Adaptive Study to Investigate the Antiviral Effect, Safety, Tolerability and Pharmacokinetics of VH3739937 in Treatment-Naïve Adults Living with HIV-1
This study is testing a new medicine, VH3739937, for people recently diagnosed with HIV. We want to see how well it lowers the amount of virus in the blood and if it's safe to use. Some participants will receive a dummy pill (placebo) instead of the actual medicine.
Poland · Italy · Greece - recruitingTherapeutic exploratory (Phase II)
A Randomized, Double-Blind, Placebo-Controlled, Trial to Investigate the Antiviral Effect, Safety, Tolerability and Pharmacokinetics of Orally Administered Capsid Inhibitors in HIV-1 Infected Treatment-Naïve Adults
This study is testing a new medicine for adults recently diagnosed with HIV. It looks at how well the medicine fights the virus, if it's safe, and how the body handles it. This could lead to better treatments for HIV.
Germany · Italy · Spain - recruitingTherapeutic exploratory (Phase II)
A Randomized, Double-Blind (Sponsor Unblinded), Placebo-Controlled, Study to Investigate the Antiviral Effect, Safety, Tolerability and Pharmacokinetics of VH4524184 in HIV-1 Infected Treatment Naïve Adults
This study is testing a new medicine, VH4524184, for adults who have HIV-1 but haven't started treatment yet. We want to see how well it fights the virus, if it's safe to use, and how the body handles it. It's an early-stage study to understand its effects.
Spain · Italy - active not recruitingPHASE3
A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Adults Who Have Not Previously Taken Antiretroviral Therapy
This study looks at two different daily pill combinations for adults newly diagnosed with HIV. It compares a two-drug treatment with a three-drug treatment to see which is safer and works better for controlling the virus.
Argentina · Belgium · Denmark - active not recruitingPHASE3
Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants
This study looks at whether switching from daily tablets to monthly injections can keep HIV under control in adults. It's for people whose HIV is already well-managed with current medication, testing a new long-acting injectable treatment.
United States · Canada · France - recruitingPHASE3
A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1
This study looks at a new long-acting medicine for people with HIV whose current treatment isn't fully controlling the virus. It checks how well it works and if it's safe. We also want to know what patients think about it.
United States · Argentina · Belgium - not yet recruitingPHASE4
The Antiretroviral Speed Access Program Switch (ASAP-Switch) Study
This study for people living with HIV who have recently moved to Quebec looks at how easy and helpful it is to switch to a new, single-pill HIV treatment called B/F/TAF. We want to understand their experiences with this new medicine and their journey with HIV care in Canada.
Canada - recruitingPHASE3
A Study to Investigate Cabotegravir Ultra Long-Acting (CAB ULA) Plus Rilpivirine Ultra Long-Acting (RPV ULA) in Adults and Adolescents With HIV Who Are Virologically Suppressed
This study is testing a new, very long-acting injectable treatment for HIV. It's for adults and teenagers whose HIV is already well-controlled with daily pills. The study will compare how safe and effective this new injectable treatment is compared to other long-acting injections already available, to see if it can keep HIV under control.
United States · Argentina · Australia - recruiting
Study of Autophagy and the Effects of GALIG Gene Products in HIV-1 Infected Patients Who Are Under Antiretroviral Therapy Since Primary-infection, Chronic Phase, or Never Treated.
This study looks at how HIV affects a process called autophagy in cells. We want to understand why some HIV patients still have health issues, even when their treatment is working well. We're comparing different groups of patients and healthy people to learn more.
France - active not recruitingPHASE3
Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults
This study looks into switching adults with HIV, who are already successfully managing their condition with daily pills, to a new treatment of long-acting injections given every month. It aims to see if these injections work just as well and are safe.
United States · Argentina · Australia - recruiting
Pharmacokinetics of Antiretroviral Agents in HIV-infected Pregnant Women.
This study looks at how HIV medicines work in pregnant women. Pregnancy can change how the body handles medicines, so researchers want to ensure the current doses are still effective for both mother and baby. We're studying several common HIV drugs.
Belgium · Germany · Ireland - active not recruitingPHASE2, PHASE3
DTG/3TC Fixed Dose Formulations for the Maintenance of Virological Suppression in Children With HIV Infection Aged 2 to <15 Years Old
This study looks at a two-drug treatment (Dolutegravir and Lamivudine) for children and young people with HIV, aged 2 to 15. It aims to see if it's as safe and effective as their current three-drug therapy.
South Africa · Spain · Thailand - recruiting
HIV and Changes in the Gut Microbiome After Changes in Antiretroviral Therapy (ART)
This study looks at how HIV medicine affects the 'good' bacteria in our gut. Researchers want to see if changing HIV treatment also changes these gut bacteria. Understanding this could help doctors choose the best treatment for each person.
United Kingdom - active not recruitingPHASE2, PHASE3
Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV
This study looks at new ways to treat HIV in children. It's testing if certain medicines (ATV/co, DRV/co, F/TAF) are safe and work well for children aged 4 weeks to 17 years. The goal is to find better treatment options for young people living with HIV.
United States · Argentina · South Africa - active not recruitingPHASE1
A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV
This study looks at new ways to reduce the amount of hidden HIV in the body. It tests a new drug, VH3810109, with or without an existing drug, Fostemsavir, in people with HIV who are new to treatment or are already on treatment.
United States · Belgium · Denmark